Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-1

NCT02600611 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

600

Enrollment

INDUSTRY

Sponsor class

Conditions

Skin Structures and Soft Tissue Infections

Interventions

DRUG: iclaprim
DRUG: vancomycin

Sponsor

Motif Bio